As such, this study was conducted to clarify the effects and effectiveness of Ozurdex in comparison with three intravitreal injections (two with anti-VEGF and one with cortisone) treating BRVO-ME for a period of 6 months after treatment, thereby helping ophthalmologists to choose the best treatment scheme for ME due to retinal vein occlusions. The gene discussed is VEGFA; the disease is retinal vein occlusion.